nach oben

Calcified Tissue International

Erschienen in:

11.08.2015 | Review

Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies

verfasst von: Pedro Esbrit, Sabina Herrera, Sergio Portal-Núñez, Xavier Nogués, Adolfo Díez-Pérez

Erschienen in: Calcified Tissue International | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

The only bone anabolic agent currently available for osteoporosis treatment is parathyroid hormone (PTH)—either its N-terminal 1–34 fragment or the whole molecule of 1–84 aminoacids—whose intermittent administration stimulates new bone formation by targeting osteoblastogenesis and osteoblast survival. PTH-related protein (PTHrP) is an abundant factor in bone which shows N-terminal homology with PTH and thus exhibits high affinity for the same PTH type 1 receptor in osteoblasts. Therefore, it is not surprising that intermittently administered N-terminal PTHrP peptides induce bone anabolism in animals and humans. Furthermore, the C-terminal region of PTHrP also elicits osteogenic features in vitro in osteoblastic cells and in various animal models of osteoporosis. In this review, we discuss the current concepts about the cellular and molecular mechanisms whereby PTHrP may induce anabolic actions in bone. Pre-clinical studies and clinical data using N-terminal PTHrP analogs are also summarized, pointing to PTHrP as a promising alternative to current bone anabolic therapies.

McCauley LK, John Martin T (2012) Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res 27:1231–1239CrossRefPubMed

Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AS, Stewart AF (1996) Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76:127–173PubMed

Yang KH, dePapp AE, Soifer NE, Dreyer BE, Wu TL, Porter SE, Bellantoni M, Burtis WJ, Insogna KL, Broadus AE, Philbrick WM, Stewart AF (1994) Parathyroid hormone-related protein: evidence for isoform- and tissue-specific posttranslational processing. Biochemistry 33:7460–7469CrossRefPubMed

Andrews NA (2013) Conversations with pioneers in the bone field: T. John Martin. IBMS BoneKEy 10, Article number: 339. doi:10.1038/bonekey.2013.73

Cupp ME, Nayak SK, Adem AS, Thomsen WJ (2013) Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J Pharmacol Exp Ther 345:404–418CrossRefPubMed

Thomas J, Gardella TJ, Vilardaga J-P (2015) International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors—Family BG protein-coupled receptors. Pharmacol Rev 67:310–337CrossRef

Whitfield JF (2007) Parathyroid hormone-related protein (PTHrP): an ancient string of cytokines with many known and still unknown functions. In: Luparello C (ed) Novel aspects of PTHrP physiopathology. Nova Science Publishers, Inc., New York, pp 1–25

Valín A, Guillén C, Esbrit P (2001) C-terminal parathyroid hormone-related protein (PTHrP) (107-139) stimulates intracellular Ca²⁺ through a receptor different from the type 1 PTH/PTHrP receptor in osteoblastic osteosarcoma UMR 106 cells. Endocrinology 142:2752–2759PubMed

John J, Grzesiak JJ, Burton DW, Deftos LJ, Bouvet M (2006) Identification of DU 145 prostate cancer cell proteins that bind to the carboxy-terminal peptide of human PTHrP in vitro. Peptides 27:1898–1901CrossRef

10.

Dean T, Vilardaga JP, Potts JT Jr, Gardella TJ (2008) Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 22:156–166CrossRefPubMedPubMedCentral

11.

Karaplis AC, Vautour L (1997) Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development. Curr Opin Nephrol Hypertens 6:308–313CrossRefPubMed

12.

Miao D, Li J, Xue Y, Su H, Karaplis AC, Goltzman D (2004) Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 145:3554–3562CrossRefPubMed

13.

Amizuka N, Karaplis AC, Henderson JE, Warshawsky H, Lipman ML, Matsuki Y, Ejiri S, Tanaka M, Izumi N, Ozawa H, Goltzman D (1996) Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol 175:166–176CrossRefPubMed

14.

Lanske B, Amling M, Neff L, Guiducci J, Baron R, Kronenberg HM (1999) Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J Clin Invest 104:399–407CrossRefPubMedPubMedCentral

15.

Miao D, Su H, He B, Gao J, Xia Q, Zhu M, Gu Z, Goltzman D, Karaplis AC (2008) Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci USA 105:20309–20314CrossRefPubMedPubMedCentral

16.

Toribio RE, Brown HA, Novince CM, Marlow B, Hernon K, Lanigan LG, Hildreth BE 3rd, Werbeck JL, Shu ST, Lorch G, Carlton M, Foley J, Boyaka P, McCauley LK, Rosol TJ (2010) The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J 24:1947–1957CrossRefPubMedPubMedCentral

17.

Kronenberg HM (2006) PTHrP and skeletal development. Ann NY Acad Sci 1068:1–13CrossRefPubMed

18.

Wang M, Van Houten JN, Nasiri AR, Tommasini SM, Broadus AE (2014) Periosteal PTHrP regulates cortical bone modeling during linear growth in mice. J Anat 225:71–82CrossRefPubMedPubMedCentral

19.

Miao D, He B, Jiang Y, Kobayashi T, Soroceanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC (2005) Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115:2402–2411CrossRefPubMedPubMedCentral

20.

Suda N, Gillespie MT, Traianedes K, Zhou H, Ho PW, Hards DK, Allan EH, Martin TJ, Moseley JM (1996) Expression of parathyroid hormone-related protein in cells of osteoblast lineage. J Cell Physiol 166:94–104CrossRefPubMed

21.

Chen H-L, Demiralp B, Schneider A, Koh AJ, Silve C, Wang CY, McCauley LK (2002) Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 277:19374–19381CrossRefPubMed

22.

Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O’Brien CA, Manolagas SC, Jilka RL (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. J Biol Chem 278:50259–50272CrossRefPubMed

23.

Alonso V, de Gortázar AR, Ardura JA, Andrade-Zapata I, Alvarez-Arroyo MV, Esbrit P (2008) Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol 217:717–727CrossRefPubMed

24.

Maycas M, Ardura JA, Fernández de Castro L, Bravo B, Gortázar AR, Esbrit P (2015) Role of the parathyroid hormone type 1 receptor (PTH1R) as a mechanosensor in osteocyte survival. J Bone Miner Res 30:1231–1244CrossRefPubMed

25.

Gesty-Palmer D, Luttrell LM (2011) “Biasing” the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol 164:59–67CrossRefPubMedPubMedCentral

26.

Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK (2007) Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 22:951–964CrossRefPubMed

27.

Canalis E, McCarthy TL, Centrella M (1990) Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis. Endocrinology 126:1806–1812CrossRefPubMed

28.

De Gortázar AR, Alonso V, Alvarez-Arroyo MV, Esbrit P (2006) Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 79:360–369CrossRefPubMed

29.

Rodríguez-de la Rosa L, López-Herradón A, Portal-Núñez S, Murillo-Cuesta S, Lozano D, Cediel R, Varela-Nieto I, Esbrit P (2014) Treatment with N- and C-terminal peptides of parathyroid hormone-related protein partly compensates the skeletal abnormalities in IGF-I deficient mice. PLoS One 9:e87536CrossRefPubMedPubMedCentral

30.

Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2005) Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 280:33132–33140CrossRefPubMed

31.

Portal-Núñez S, Lozano D, Fernández de Castro L, de Gortázar AR, Nogués X, Esbrit P (2010) Alterations of the Wnt/β-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett 584:3095–30100CrossRefPubMed

32.

de Castro LF, Lozano D, Portal-Núñez S, Maycas M, De la Fuente M, Caeiro JR, Esbrit P (2012) Comparison of the skeletal effects induced by daily administration of PTHrP (1-36) and PTHrP (107-139) to ovariectomized mice. J Cell Physiol 227:1752–1760CrossRefPubMed

33.

López-Herradón A, Portal-Núñez S, García-Martín A, Lozano D, Pérez-Martínez FC, Ceña V, Esbrit P (2013) Inhibition of the canonical Wnt pathway by high glucose can be reversed by parathyroid hormone-related protein in osteoblastic cells. J Cell Biochem 114:1908–1916CrossRefPubMed

34.

Weir EC, Lowik CW, Paliwal I, Insogna KL (1996) Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related protein. J Bone Miner Res 11:1474–1481CrossRefPubMed

35.

Guillén C, Martínez P, de Gortázar AR, Martínez ME, Esbrit P (2002) Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by NF-κB activation in osteoblastic cells. J Biol Chem 277:28109–28117CrossRefPubMed

36.

Allan EH, Häusler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, Pompolo S, Sims NA, Gillespie MT, Onyia JE, Martin TJ (2008) EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 23:1170–1181CrossRefPubMed

37.

Henderson JE, Amizuka N, Warshawsky H, Diasotto D, Lanske BMK, Goltzman D, Karaplis AC (1995) Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol 15:4064–4075CrossRefPubMedPubMedCentral

38.

García-Martín A, Ardura JA, Maycas M, Lozano D, López-Herradón A, Portal-Núñez S, García-Ocaña A, Esbrit P (2014) Roles of nuclear localization signal of parathyroid hormone-related protein in osteoblastic cells. Mol Endocrinol 28:925–934CrossRefPubMed

39.

Hildreth BE III, Werbeck JL, Thudi NK, Deng X, Rosol TJ, Toribio RE (2010) PTHrP 1-141 and 1-86 increase in vitro bone formation. J Surg Res 162:e9–e17CrossRefPubMedPubMedCentral

40.

Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR (1999) Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 14:915–922CrossRefPubMed

41.

Fenton AJ, Kemp BE, Kent GN, Moseley JM, Zheng MH, Rowe DJ, Britto JM, Martin TJ, Nicholson GC (1991) A carboxyl-terminal peptide from the parathyroid hormone-related protein inhibits bone resorption by osteoclasts. Endocrinology 129:1762–1768CrossRefPubMed

42.

Cornish J, Callon KE, Nicholson GC, Reid IR (1997) Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo. Endocrinology 138:1299–1304PubMed

43.

García-Martín A, Acitores A, Maycas M, Villanueva-Peñacarrillo ML, Esbrit P (2013) Src kinases mediate VEGFR2 transactivation by the osteostatin domain of PTHrP to modulate osteoblastic function. J Cell Biochem 114:1404–1413CrossRefPubMed

44.

Fenton AJ, Kemp BE, Hammonds RG, Mitchelhill K, Moseley JM, Martin TJ, Nicholson GC (1991) A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of parathyroid hormone-related protein, PTHrP (107–111). Endocrinology 129:3424–3426CrossRefPubMed

45.

Manzano M, Lozano D, Arcos D, Portal-Núñez S, Orden CL, Esbrit P, Vallet-Regí M (2011) Comparison of the osteoblastic activity conferred on Si-doped hydroxyapatite scaffolds by different osteostatin coatings. Acta Biomater 7:3555–3562CrossRefPubMed

46.

Stewart AF (2002) Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. J Bone Miner Res 17:758–762CrossRefPubMed

47.

Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434–1446CrossRefPubMedPubMedCentral

48.

Migliore A, Broccoli S, Massafra U, Bizzi E, Frediani B (2012) Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis. Curr Med Res Opin 28:467–473CrossRefPubMed

49.

Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838–1845CrossRefPubMedPubMedCentral

50.

Kramer I, Keller H, Leupin O, Kneissel M (2010) Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21:237–244CrossRefPubMed

51.

Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96:1555–1559CrossRefPubMed

52.

Polyzos SA, Makras P, Efstathiadou Z, Anastasilakis AD (2015) Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Expert Opin Invest Drugs 24:145–157CrossRef

53.

Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517–1525CrossRefPubMed

54.

Vickery BH, Avnur Z, Cheng Y, Chiou SS, Leaffer D, Caulfield JP, Kimmel DB, Ho T, Krstenansky JL (1996) RS-66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomized osteopenic rats. J Bone Miner Res 11:1943–1951CrossRefPubMed

55.

XuJ RongH, JiH Wang D, Wang J, Zhang W, Zhang Y (2013) Effects of different dosages of parathyroid hormone-related protein 1–34 on the bone metabolism of the ovariectomized rat model of osteoporosis. Calcif Tissue Int 93:276–287CrossRef

56.

Fernández de Castro L, Lozano D, Dapía S, Portal-Núñez S, Caeiro JR, Gómez-Barrena E, Esbrit P (2010) Role of the N- and C-terminal fragments of parathyroid hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng Part A 16:1157–1168CrossRef

57.

Lozano D, de Castro LF, Dapía S, Andrade-Zapata I, Manzarbeitia F, Alvarez-Arroyo MV, Gómez-Barrena E, Esbrit P (2009) Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 150:2027–2035CrossRefPubMed

58.

Wang H, Liu J, Yin Y, Wu J, Wang Z, Miao D, Sun W (2014) Recombinant human parathyroid hormone related protein 1-34 and 1-84 and their roles in osteoporosis treatment. PLoS ONE 9:e88237CrossRefPubMedPubMedCentral

59.

Doyle N, Varela A, Smith SY, Guldberg R, Hattersley G (2013) Long term effect of BA058, a novel human PTHrP analog, restores bone mass in the aged osteopenic ovariectomized cynomolgus monkey. J Bone Miner Res 28(Suppl 1) [abstract]

60.

Lozano D, Fernández-de-Castro L, Portal-Núñez S, López-Herradón A, Dapía S, Gómez-Barrena E, Esbrit P (2011) The C-terminal fragment of parathyroid hormone-related peptide promotes bone formation in diabetic mice with low turnover osteopenia. Br J Pharmacol 162:1424–1438CrossRefPubMedPubMedCentral

61.

Rihani-Basharat S, Lewinson D (1997) PTHrP (107–111) inhibits in vivo resorption that was stimulated by PTHrP (1–34) when applied intermittently to neonatal mice. Calcif Tissue Int 61:426–428CrossRefPubMed

62.

Kyllönen L, D’Este M, Alini M, Eglin D (2015) Local drug delivery for enhancing fracture healing in osteoporotic bone Acta Biomat 11:412–434

63.

Yukata K, Xie C, Li TF, Takahata M, Hoak D, Kondabolu S, Zhang X, Awad HA, Schwarz EM, Beck CA, Jonason JH, O’Keefe RJ (2014) Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1-34 treatment. Bone 62:79–89CrossRefPubMedPubMedCentral

64.

Bostrom MPG, Gamradt SC, Asnis P, Vickery BH, Hill E, Avnur Z, Waters RV (2000) Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone 26:437–442CrossRefPubMed

65.

Trejo CG, Lozano D, Manzano M, Doadrio JC, Salinas AJ, Dapía S, Gómez-Barrena E, Vallet-Regí M, García-Honduvilla N, Buján J, Esbrit P (2010) The osteoinductive properties of mesoporous silicate coated with osteostatin in a rabbit femur cavity defect model. Biomaterials 31:8564–8573CrossRefPubMed

66.

Lozano D, Trejo CG, Gómez-Barrena E, Manzano M, Doadrio JC, Salinas AJ, Vallet-Regí M, García-Honduvilla N, Esbrit P, Buján J (2012) Osteostatin-loaded onto mesoporous ceramics improves the early phase of bone regeneration in a rabbit osteopenia model. Acta Biomater 8:2317–2323CrossRefPubMed

67.

Lozano D, Sánchez-Salcedo S, Portal-Núñez S, Vila M, López-Herradón A, Ardura JA, Mulero F, Gómez-Barrena E, Vallet-Regí M, Esbrit P (2014) Parathyroid hormone-related protein (107–111) improves the bone regeneration potential of gelatin–glutaraldehyde biopolymer-coated hydroxyapatite. Acta Biomater 10:3307–3316CrossRefPubMed

68.

Coletta DJ, Lozano D, Rocha-Oliveira AA, Mortarino P, Bumaguin GE, Vitelli E, Vena R, Missana L, Jammal MV, Portal-Núñez S, Pereira M, Esbrit P, Feldman S (2014) Characterization of hybrid bioactive glass–polyvinyl alcohol scaffolds containing a PTHrP-derived pentapeptide as implants for tissue engineering applications. Open Biomed Eng J 8:20–27CrossRefPubMedPubMedCentral

69.

van der Stok J, Lozano D, Chin Chai Y, Yavari SA, Bastidas Coral AP, Verhaar J, Gómez-Barrena E, Schrooten J, Jahr H, Zadpoor AA, Esbrit P, Weinans H (2015) Osteostatin-coated porous titanium implants improve early bone regeneration in cortical bone defects in rats. Tissue Eng Part A 21:1495–1506CrossRefPubMed

70.

Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003) Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 88:1603–1609CrossRefPubMed

71.

Plotkin H, Gundberg C, Mitnick M, Stewart AF (1998) Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83:2786–2791PubMed

72.

Horwitz MJ, Tedesco MB, Garcia-Ocaña A, Sereika SM, Prebehala L, Bisello A, Hollis BW, Gundberg CM, Stewart AF (2010) Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 95:1279–1287CrossRefPubMedPubMedCentral

73.

Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocaña A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569–575CrossRefPubMed

74.

Horwitz MJ, Augustine M, Kahn L, Martin E, Oakley CC, Carneiro RM, Tedesco MB, Laslavic A, Sereika SM, Bisello A, García-Ocaña A, Gundberg CM, Cauley JA, Stewart AF (2013) A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J Bone Miner Res 28:2266–2276CrossRefPubMedPubMedCentral

75.

Leder BZ, O’DeaLStL Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle R, Hattersley G (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100:697–706CrossRefPubMed

76.

Miller PD, Leder BZ, Hattersley G, Lau E, Alexandersen P, Hala T, Mustatea S, Nedergaard BS, Krogsaa A, Slesinger J, Zerbini CAF, Valter I, Visockiene Z, Jendrych B, Kulak CA, Marquez F, Harris AG, Williams GC, Hu M-Y, Riis BJ, Russo LA, Christiansen C (2015) Effects of abaloparatide on vertebral and non-vertebral fracture incidence in postmenopausal women with osteoporosis—results of the phase 3 ACTIVE trial. In: The Endocrine Society’s 97th Annual Meeting, 5–8 Mar, 2015 San Diego, USA [Abstract LB-OR01-3]

77.

Yates J, Miller PD, Bolognese MA, Woodson G, Valter I, Clarkin M, Hattersley G, Hansen K, Karsdal M, Christiansen C (2014) A transdermal patch delivering the PTHrP analog, abaloparatide (BA058) dose-dependently increases spine and hip BMD compared to placebo. In: The Endocrine Society’s 96th Annual Meeting, 21–24 June, 2014 Chicago, USA [Abstract OR22-4]

Titel: Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies
verfasst von: Pedro Esbrit
Sabina Herrera
Sergio Portal-Núñez
Xavier Nogués
Adolfo Díez-Pérez
Publikationsdatum: 11.08.2015
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 4/2016
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-015-0050-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Pharmacologic Options for the Treatment of Sarcopenia

New Targets and New Treatments: Recent Advances in the Treatment of Musculoskeletal Disease

Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures

Alkaline Phosphatase and Hypophosphatasia

FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism

Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis